ACT-02

N/A

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameACT-02
Drug Alias Nameprolyl oligopeptidase (POP) inhibitor (Iproteos)IPR-166Act-02ACT-02
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProlyl endopeptidase inhibitors
TargetsProlyl endopeptidase
Therapy Area/IndicationsCognition DisordersParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIproteos Investment SL
China Registration ClassN/A

Develop Information

Active CompaniesAccure Therapeutics SL
Inactive CompaniesIproteos Investment SL
Active IndicationsCognition DisordersParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A